# Letter by Wu et al Regarding Article, “G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice”. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-receptor-2-phosphorylation-diabetic-heart-injury/ > **Published:** 2026-03-30T19:04:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:36-04:00 > **Clinical Summary:** Explore how cannabinoid receptor 2 phosphorylation by GRK3 impacts diabetic heart injury and potential implications for diabetic cardiovascular health. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic DiabetesCardiovascularCb2MechanismResearch Journal Circulation Study Type Clinical Study Population Human participants Why This Matters This mechanistic research illuminates how cannabinoid receptor 2 (CB2) function may be impaired in diabetic heart disease through specific protein kinase interactions. Understanding these molecular pathways could inform future therapeutic approaches using cannabinoid-based interventions for diabetic cardiovascular complications. Clinical Summary This appears to be a letter responding to previous research on G protein-coupled receptor kinase 3 (GRK3) and its role in phosphorylating cannabinoid receptor 2 in diabetic heart injury. The original work likely demonstrated that GRK3 directly phosphorylates [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), potentially reducing their protective function in diabetic cardiovascular disease. While the specific contents of Wu et al’s letter are not detailed, such correspondence typically addresses methodological considerations or clinical implications of the mechanistic findings. The research contributes to understanding how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) may be dysregulated in diabetes-related heart disease. Dr. Caplan’s Take “This type of mechanistic research is valuable for understanding cannabinoid receptor function in disease states, but we’re still years away from translating these molecular insights into clinical interventions. The complexity of cannabinoid receptor regulation reminds us why clinical outcomes don’t always match what we might predict from receptor studies.” Clinical Perspective 🧠 Clinicians should view this as foundational science that may eventually inform therapeutic development rather than actionable clinical guidance. Patients with diabetes and cardiovascular disease should continue evidence-based treatments while researchers work to understand how cannabinoid system dysfunction might be therapeutically targeted in the future. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Letter%20by%20Wu%20et%20al%20Regarding%20Article%2C%20%22G%20Protein-Coupled%20Receptor%20Kinase%203%20Exace...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41911349/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41911349/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Letter%20by%20Wu%20et%20al%20Regarding%20Article%2C%20%22G%20Protein-Coupled%20Receptor%20Kinase%203%20Exace...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41911349/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41911349/](https://pubmed.ncbi.nlm.nih.gov/41911349/) Table of Contents - [FAQ](#FAQ)[What is the clinical significance of CB2 receptor phosphorylation in diabetic heart disease?](#What_is_the_clinical_significance_of_CB2_receptor_phosphorylation_in_diabetic_heart_disease) - [How does this finding impact current cannabis-based treatments for diabetic patients?](#How_does_this_finding_impact_current_cannabis-based_treatments_for_diabetic_patients) - [Should diabetic patients avoid cannabis based on these findings?](#Should_diabetic_patients_avoid_cannabis_based_on_these_findings) - [What are the potential therapeutic implications of targeting GRK3 in diabetic heart disease?](#What_are_the_potential_therapeutic_implications_of_targeting_GRK3_in_diabetic_heart_disease) - [How does this research affect the understanding of the endocannabinoid system in diabetes?](#How_does_this_research_affect_the_understanding_of_the_endocannabinoid_system_in_diabetes) - [Related](#Related) ## FAQ #### What is the clinical significance of CB2 receptor phosphorylation in diabetic heart disease? This research identifies a novel mechanism where G protein-coupled receptor kinase 3 (GRK3) directly phosphorylates cannabinoid receptor 2 (CB2), potentially worsening diabetic heart injuries. Understanding this pathway may lead to new therapeutic targets for protecting the heart in diabetic patients. #### How does this finding impact current cannabis-based treatments for diabetic patients? The study suggests that [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) dysfunction through phosphorylation may limit the cardioprotective benefits of [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) in diabetes. This represents early-stage research that requires further validation before changing clinical recommendations for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in diabetic cardiovascular disease. #### Should diabetic patients avoid cannabis based on these findings? Current evidence is insufficient to recommend avoiding cannabis based solely on this mechanistic study. Patients should continue following existing clinical guidelines and discuss any concerns with their healthcare providers, as this research represents preliminary findings requiring further investigation. #### What are the potential therapeutic implications of targeting GRK3 in diabetic heart disease? GRK3 inhibition could theoretically preserve [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) function and reduce diabetic heart injuries, representing a novel therapeutic approach. However, this concept requires extensive preclinical and clinical validation before any therapeutic applications can be considered. #### How does this research affect the understanding of the endocannabinoid system in diabetes? This study reveals a new layer of complexity in how diabetes affects the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), specifically through post-translational modification of [CB2 receptors](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/). It highlights that diabetic complications may involve not just altered cannabinoid levels, but also impaired receptor function through phosphorylation mechanisms. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Letter by Wu et al Regarding Article, \”G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice\”.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41911349/”, “about”: “circulation clinical study letter wu et”, “isPartOf”: “Circulation”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Letter by Wu et al Regarding Article, “G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice”.](https://cedclinic.com/diabetic-heart-disease-cannabinoid-receptor-grk3-research/) Detailed exploration of GRK3's role in phosphorylating cannabinoid receptor 2 and its impact on diabetic heart disease. [Read More](https://cedclinic.com/diabetic-heart-disease-cannabinoid-receptor-grk3-research/) [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) An analysis of the complex interactions between opioids and cannabis, relevant for patients with chronic conditions. [Explore Insights](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) [The effect of cannabis use on the time course of positive and negative affect in the daily life of youth.](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/) Study examining how [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) influences emotional states over time in young populations. [Learn More](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).